Dandan Yin, Yan Guo, Renru Han, Yang Yang, Demei Zhu, Fupin Hu
{"title":"A modified Kirby-Bauer disc diffusion (mKB) method for accurately testing tigecycline susceptibility: a nation-wide multicenter comparative study.","authors":"Dandan Yin, Yan Guo, Renru Han, Yang Yang, Demei Zhu, Fupin Hu","doi":"10.1099/jmm.0.001671","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction.</b> Tigecycline is one of the important antibiotics available for treating infection caused by multiple-drug resistant pathogens. However, the conventional AST methods which are commonly used in clinical microbiology laboratories usually lead to false intermediate or resistant results in testing tigecycline susceptibility, and further mislead clinical antimicrobial therapies.<b>Hypothesis.</b> The modified Kirby-Bauer disc diffusion (mKB) method was performed based on the traditional standard Kirby-Bauer disc diffusion (sKB) method.<b>Aim</b>. To evaluate a modified Kirby-Bauer disc diffusion (mKB) method for tigecycline susceptibility testing, for the purpose of providing accurate tigecycline susceptibility results in clinical practice.<b>Methodology.</b> A total of 4271 nonduplicate clinical strains were isolated from 37 hospitals across China to perform the mKB method, standard Kirby-Bauer disc diffusion (sKB) method, comparing with the reference broth microdilution (BMD) according to the CLSI. Parameters of categorical agreement (CA), minor errors (mE), major errors (ME), and very major errors (VME) were used in this methodological evaluation research.<b>Results.</b> BMD testing showed that 91.3-98.9 % of the <i>A. baumannii</i>, <i>K. pneumoniae</i>, <i>E. coli</i>, <i>E. cloacae</i>, <i>S. marcescens</i>, and <i>C. freundii</i> strains were susceptible, while 0-3.1% strains were resistant to tigecycline. When testing <i>A. baumannii</i>, mKB demonstrated higher CA than sKB (90.6 % vs 44.8 %) compared to reference BMD. The mE (9.0 % vs 45.2 %), ME (0.5 % vs 10.6 %) and VME (both 0 %) all satisfied the acceptability criteria. mKB also showed higher CA (87.2 % vs 52.0 %) than sKB in comparison with BMD when testing <i>Enterobacterales</i> (mainly <i>K. pneumonia</i>). The ME (0.45 % vs 8.1 %) and VME (both 0 %) but not mE (12.4 % vs 40.4 %) met the acceptability criteria.<b>Conclusion.</b> The mKB method can test bacterial susceptibility to tigecycline more accurately than sKB. For the tigecycline-intermediate or -resistant strains by sKB method, BMD or mKB method should be used to verify the results and report reliable tigecycline susceptibility results.</p>","PeriodicalId":16343,"journal":{"name":"Journal of medical microbiology","volume":"72 8","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of medical microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1099/jmm.0.001671","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction. Tigecycline is one of the important antibiotics available for treating infection caused by multiple-drug resistant pathogens. However, the conventional AST methods which are commonly used in clinical microbiology laboratories usually lead to false intermediate or resistant results in testing tigecycline susceptibility, and further mislead clinical antimicrobial therapies.Hypothesis. The modified Kirby-Bauer disc diffusion (mKB) method was performed based on the traditional standard Kirby-Bauer disc diffusion (sKB) method.Aim. To evaluate a modified Kirby-Bauer disc diffusion (mKB) method for tigecycline susceptibility testing, for the purpose of providing accurate tigecycline susceptibility results in clinical practice.Methodology. A total of 4271 nonduplicate clinical strains were isolated from 37 hospitals across China to perform the mKB method, standard Kirby-Bauer disc diffusion (sKB) method, comparing with the reference broth microdilution (BMD) according to the CLSI. Parameters of categorical agreement (CA), minor errors (mE), major errors (ME), and very major errors (VME) were used in this methodological evaluation research.Results. BMD testing showed that 91.3-98.9 % of the A. baumannii, K. pneumoniae, E. coli, E. cloacae, S. marcescens, and C. freundii strains were susceptible, while 0-3.1% strains were resistant to tigecycline. When testing A. baumannii, mKB demonstrated higher CA than sKB (90.6 % vs 44.8 %) compared to reference BMD. The mE (9.0 % vs 45.2 %), ME (0.5 % vs 10.6 %) and VME (both 0 %) all satisfied the acceptability criteria. mKB also showed higher CA (87.2 % vs 52.0 %) than sKB in comparison with BMD when testing Enterobacterales (mainly K. pneumonia). The ME (0.45 % vs 8.1 %) and VME (both 0 %) but not mE (12.4 % vs 40.4 %) met the acceptability criteria.Conclusion. The mKB method can test bacterial susceptibility to tigecycline more accurately than sKB. For the tigecycline-intermediate or -resistant strains by sKB method, BMD or mKB method should be used to verify the results and report reliable tigecycline susceptibility results.
介绍。替加环素是治疗多重耐药病原菌感染的重要抗生素之一。然而,临床微生物实验室常用的传统AST方法在检测替加环素药敏时往往会导致错误的中间或耐药结果,从而进一步误导临床抗菌治疗。在传统标准Kirby-Bauer盘扩散法(sKB)的基础上,建立了改进的Kirby-Bauer盘扩散法(mKB)。评价改良的Kirby-Bauer椎间盘扩散法(mKB)用于替加环素药敏试验的效果,以期在临床实践中提供准确的替加环素药敏结果。从全国37家医院分离临床非重复菌株4271株,采用mKB法、标准Kirby-Bauer圆盘扩散法(sKB)与对照肉汤微量稀释法(BMD)进行比较。本方法学评价研究采用了分类一致性(CA)、小误差(mE)、大误差(mE)和特大误差(VME)等参数。BMD检测结果显示,鲍曼不动杆菌、肺炎克雷伯菌、大肠杆菌、阴沟不动杆菌、粘质不动杆菌和弗氏不动杆菌对替加环素的易感率为91.3 ~ 98.9%,耐药率为0 ~ 3.1%。当检测鲍曼不动杆菌时,与参考骨密度相比,mKB显示出比sKB更高的CA (90.6% vs 44.8%)。mE (9.0% vs 45.2%)、mE (0.5% vs 10.6%)和VME(均为0%)均满足可接受标准。当检测肠杆菌(主要是肺炎克雷伯菌)时,mKB也比BMD显示更高的CA (87.2% vs 52.0%)。ME (0.45% vs 8.1%)和VME(均为0%)符合可接受标准,ME (12.4% vs 40.4%)不符合可接受标准。mKB法检测细菌对替加环素的敏感性比sKB法更准确。对于sKB法检测到的替加环素中耐药菌株,应采用BMD或mKB法对结果进行验证,报告可靠的替加环素药敏结果。
期刊介绍:
Journal of Medical Microbiology provides comprehensive coverage of medical, dental and veterinary microbiology, and infectious diseases. We welcome everything from laboratory research to clinical trials, including bacteriology, virology, mycology and parasitology. We publish articles under the following subject categories: Antimicrobial resistance; Clinical microbiology; Disease, diagnosis and diagnostics; Medical mycology; Molecular and microbial epidemiology; Microbiome and microbial ecology in health; One Health; Pathogenesis, virulence and host response; Prevention, therapy and therapeutics